Eczema (Atopic Dermatitis): The Evidence-Based Supplement Protocol

← Back to articles

Atopic dermatitis (eczema) is driven by skin-barrier dysfunction (often filaggrin mutations) plus IL-4/IL-13-dominated type-2 inflammation. The interventions that actually control it are topical: emollients used liberally, topical corticosteroids and calcineurin inhibitors for flares, and — for moderate-to-severe disease — the biologic dupilumab and JAK inhibitors. Supplements play a secondary role. Two distinct questions matter: can a supplement treat established eczema, and can one prevent it in high-risk infants? The answers differ, and several heavily marketed oils have been shown not to work. This page grades the evidence, strongest first.

Vitamin D — moderate evidence for repletion, best signal in deficiency and winter

Vitamin D is the supplement with the most consistent therapeutic signal. A meta-analysis of randomized trials reported a clinically meaningful reduction in eczema severity (SCORAD mean difference about -5.8 versus placebo) with supplementation (PMID 27061361). The most rigorous single trial — a placebo-controlled RCT of 1,000 IU/day cholecalciferol in Mongolian children with winter-related eczema — found a significant improvement in EASI score over one month in a population very likely to be deficient (PMID 25282565). An EAACI task-force systematic review of pediatric dietary interventions reached more cautious conclusions about vitamin D, underscoring that benefit is clearest where baseline status is low (PMID 38783644). Evidence grade: moderate, strongest in winter and in documented deficiency. A pragmatic approach is to test 25-OH-D and replete toward ~30 ng/mL using standard doses rather than megadosing. See our vitamin D dosing guide.

Omega-3 (EPA/DHA) — limited; small SCORAD signal from small trials

The therapeutic evidence for omega-3 in established eczema rests on small studies. A randomized, double-blind controlled pilot trial of 5.4 g/day DHA for eight weeks produced a significant fall in SCORAD versus an isoenergetic control, alongside reduced IgE synthesis in vitro — but the authors explicitly called for confirmation in a larger study (PMID 18241260). The Cochrane review of dietary supplements for established eczema judged the two fish-oil trials available as only a "possible modest benefit" requiring a much larger registered trial before it could change practice (PMID 22336810). Evidence grade: limited. A reasonable trial is 1.5–3 g EPA+DHA daily for ~12 weeks. Cautions: high doses can mildly raise bleeding risk and interact with anticoagulants.

Probiotics — for prevention in at-risk infants, not for treating established disease

This is the most common misunderstanding. The strongest probiotic evidence is preventive. A meta-analysis of 14 studies found that giving probiotics during pregnancy and/or early infancy reduced the incidence of atopic dermatitis (relative risk about 0.79), with a similar effect whether the mother, the infant, or both received them (PMID 22441545); a 2020 prevention review estimated probiotics could lower AD incidence by roughly 20% while noting substantial heterogeneity between trials (PMID 32419030). For treating eczema that already exists, the EAACI meta-analysis did find that probiotics (alone or with prebiotics) significantly reduced SCORAD in children, though the broader literature is mixed and strain-dependent (PMID 38783644). Evidence grade: moderate for prevention in high-risk infants; weak/inconsistent for treatment. Lactobacillus rhamnosus GG and certain Lactobacillus + Bifidobacterium combinations are the most studied. See our infant-eczema probiotic piece.

Zinc — correct deficiency only

Low zinc is more common in children with severe eczema, particularly with frequent skin infections, but the Cochrane review found a single small trial of zinc sulphate showed no benefit in unselected patients (PMID 22336810). Evidence grade: insufficient except to correct measured deficiency. If serum zinc is low, 15–25 mg elemental daily is reasonable; do not megadose, since chronic high zinc causes copper deficiency and does not improve eczema in zinc-replete patients.

What doesn't work / overhyped

The clearest negative finding in this whole field: a Cochrane review of 27 trials (1,596 participants) concluded that oral evening primrose oil and borage oil — both sold for their gamma-linolenic-acid content — do not improve eczema, with effects no better than placebo, and judged further trials hard to justify (PMID 23633319). It also flagged a bleeding-risk interaction between evening primrose oil and warfarin. See our EPO Cochrane piece and borage oil piece. High-dose vitamin E has no convincing eczema data (PMID 22336810), and "skin-clearing detox" formulas have no mechanism. The Cochrane authors also warned that high-dose vitamin D taken indiscriminately can cause harm — another reason to dose to a measured level. Do not replace topical therapy or a prescribed biologic with supplements in moderate-to-severe disease.

How to think about a protocol

Liberal emollient use at least twice daily plus a topical corticosteroid (or calcineurin inhibitor) for flares is the foundation and is reflected in dermatology guidelines (PMID 24813298); for severe disease, dupilumab and JAK inhibitors outperform any supplement. As adjuncts: test 25-OH-D and replete toward ~30 ng/mL (the best-supported supplement step), consider a 12-week omega-3 trial, and correct measured zinc deficiency. For an expectant parent with a strong family history of atopy, a probiotic in the third trimester continued in the infant has genuine — if modest — preventive evidence. Skip evening primrose and borage oil entirely. See the broader skin-health stack.